SGLT2-inhibition and Vascular Euphoria a Reconciliation of Vascular Health and Disease Homeostasis.

Cardiovascular Diseases / prevention & control Diabetes Mellitus, Type 2 / drug therapy Euphoria Homeostasis Humans Hypoglycemic Agents Sodium-Glucose Transporter 2 Sodium-Glucose Transporter 2 Inhibitors

Journal

The Journal of the Association of Physicians of India
ISSN: 0004-5772
Titre abrégé: J Assoc Physicians India
Pays: India
ID NLM: 7505585

Informations de publication

Date de publication:
Apr 2021
Historique:
entrez: 2 9 2021
pubmed: 3 9 2021
medline: 4 9 2021
Statut: ppublish

Résumé

The concept of SGLT2-inhibition, once regarded as a non-physiological approach to glycemia control, now finds a foundational relevance in risk-modification for cardiovascular, kidney, and metabolic outcomes, spanning beyond type-2 diabetes. Major studies have proven meaningful improvements in various clinical outcomes, with different SGLT2-i agents. Apart from glycosuria, SGLT2-inhibition is associated with several patho-physiological effects, which may contribute to the clinical benefits seen with these agents. This narrative review is an attempt to appraise the different patho-physiological effects mediated by SGLT2-inhibition, based on contemporary evidence. The review classifies these effects in the acronym of EUPHORIA, and grades the possible relevance of each effect, in improving clinical outcomes.

Identifiants

PMID: 34470191
pubmed: 34470191

Substances chimiques

Hypoglycemic Agents 0
Sodium-Glucose Transporter 2 0
Sodium-Glucose Transporter 2 Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-12

Informations de copyright

© Journal of the Association of Physicians of India 2011.

Auteurs

Mangesh Tiwaskar (M)

Consultant Physician & Diabetologist, Shilpa Medical Research Centre, Mumbai, Maharashtra.

Sanjay Kalra (S)

Consultant Endocrinologist, Bharti Hospital, Haryana.

Ganapathi Bantwal (G)

Professor and Head of the Department of Endocrinology, St. Johns Medical College & Hospital, Bengaluru, Karnataka.

Arpandev Bhattacharya (A)

Consultant Endocrinologist, Manipal Hospital, Bengaluru, Karnataka.

Manisha Sahay (M)

Professor and Head of Nephrology Department, Osmania General Hospital, Hyderabad, Telangana.

Uday Jadhav (U)

Consultant Cardiologist, MGM Hospital, Navi Mumbai, Maharashtra.

Ameya Joshi (A)

Consultant Endocrinologist, Bhaktivedanta Hospital and Research Institute, Mumbai, Maharashtra.

A K Das (AK)

Professor and Head of Endocrinology, Pondicherry Institute of Medical Sciences, Puducherry.

Dinesh Khullar (D)

Chairman - Nephrology and Renal Transplant Medicine, Department of Nephrology and Renal transplant medicine, Max Super Speciality Hospital, New Delhi.

Manash Baruah (M)

Consultant Endocrinologist, Excel care Hospitals, Guwahati, Assam.

Hitesh Punyani (H)

Consultant Diabetologist, Apollo Cradle Hospital, New Delhi.

Kamal Kishor (K)

Consultant Cardiologist, RAMA Superspeciality and Critical Care Hospital, Karnal, Haryana.

Kimi Shetty (K)

Department of Medical Affairs, Boehringer Ingelheim.

Jignesh Ved (J)

Department of Medical Affairs, Boehringer Ingelheim.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies cardiovasculaires › SGLT2-inhibition and Vascular Euphoria a...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › SGLT2-inhibition and Vascular Euphoria a...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Émotions › Euphorie › SGLT2-inhibition and Vascular Euphoria a...
questionsmedicales.fr › Phénomènes physiologiques › Homéostasie › SGLT2-inhibition and Vascular Euphoria a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › SGLT2-inhibition and Vascular Euphoria a...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › SGLT2-inhibition and Vascular Euphoria a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Protéines transporteurs de solutés › Transporteur-2 sodium-glucose › SGLT2-inhibition and Vascular Euphoria a...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Inhibiteurs du cotransporteur sodium-glucose de type 2 › SGLT2-inhibition and Vascular Euphoria a...